Skip to content
About Us
Team
Board
Business Model
Pipeline
BRM421 for Dry Eye Disease
BRM423 for Corneal Damage Repair
BRM424 for Neurotrophic Keratitis
BRM521 for Treatment of Osteoarthritis
Investors
News
Corporate Governance
Committees
Internal audit
Risk management
Major Internal Policies
Shareholder information
Financial information
Corporate Sustainability
Stakeholders
News
Career
Contact Us
繁體中文
About Us
Team
Board
Business Model
Pipeline
BRM421 for Dry Eye Disease
BRM423 for Corneal Damage Repair
BRM424 for Neurotrophic Keratitis
BRM521 for Treatment of Osteoarthritis
Investors
News
Corporate Governance
Committees
Internal audit
Risk management
Major Internal Policies
Shareholder information
Financial information
Corporate Sustainability
Stakeholders
News
Career
Contact Us
繁體中文
選單
2023/06/01
2021 Shareholder Meeting Annual Report
Post navigation
Previous
Post
Non-Confidential Corporate Deck
Next
Post
2022 First Provisional Shareholder Meeting Notice
